IP Library Granted Patent US 10,065,971
Granted Patent B2
US 10,065,971 · App. 15/315,095 · Granted Sep 4, 2018

Amide derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain

Inventors: Marina Virgili-Bernado (Barcelona, ES); Monica Alonso-Xalma (Barcelona, ES); Carlos Alegret-Molina (Barcelona, ES); Carmen Almansa-Rosales (Barcelona, ES); Ramón Merce-Vidal (Barcelona, ES)
Assignee: ESTEVE PHARMACEUTICALS S.A.
C07D498/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,065,971
App. No.
15/315,095
Granted
Sep 4, 2018
Kind
B2
Abstract

The present invention relates to compounds having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opiod receptor and more particularly to diazaspiro undecane compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain. wherein Y is n is 1 or 2; q is 1, 2, 3, 4, 5 or 6; X is a bond, —C(O)O—, —C(O)NR 8 —, —C(O)—, —O— or —C(R 4 R 4′ )—; R 1 is C(O)R 5 or S(O) 2 R 5 .

Claims (315)

1. A compound of formula (I),

wherein

Y is

n is 1 or 2;

q is 1, 2, 3, 4, 5or 6;

X is a bond, —C(O)O—, —C(O)NR 8 —, —C(O)—, —O— or —C(R 4 R 4 )—;

R 1 is C(O)R 5 or S(O) 2 R 5 ;

R 2 is substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heterocyclyl; with cycloalkyl, aryl, or heterocyclyl, if substituted, being substituted by substituents selected from the group consisting of halogen, —R 9 , —OR 9 , —NO 2 , —NR 9 R 9′″ , NR 9 C(O)R 9′ , —NR 9 S(O) 2 R 9′ , —S(O) 2 NR 9 R 9′ , —NR 9 C(O)NR 9′ R 9″ —, —SR 9 , —S(O)R 9 , S(O) 2 R 9 , —CN, haloalkyl, haloalkoxy, —C(O)OR 9 , —C(O)NR 9 R 9′ , ═O, —OCH 2 CH 2 OH, —NR 9 S(O) 2 NR 9′ R 9″ ;

R 3 and R 3 ′ are independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylheterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, with cycloalkyl, heterocyclyl or aryl, if substituted, also in alkylaryl, alkylcycloalkyl or alkylheterocyclyl, being substituted by substituents selected from the group consisting of halogen, —R 9 , and —OR 9 ;

R 4 is hydrogen, —OR 8 , substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, —C(O)OR 9 , —C(O)NR 9 R 9′ , —NR 9 C(O)R 9′ , —NR 9 R 9′″ , unsubstituted heterocyclyl, unsubstituted aryl or unsubstituted cycloalkyl;

R 4′ is hydrogen, or substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl or substituted or unsubstituted C 2-6 alkynyl;

R 5 is substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkyl aryl, substituted or unsubstituted alkyl heterocyclyl and substituted or unsubstituted alkyl cycloalkyl, —NR 8 R 8′ , wherein the cycloalkyl, aryl or heterocyclyl, if substituted, also in alkylaryl, alkylcycloalkyl or alkylheterocyclyl, being substituted by substituents selected from the group consisting of halogen, —R 9 , —OR 9 , —NO 2 , —NR 9 R 9′″ , —NR 9 C(O)R 9′ , —NR 9 S(O) 2 R 9′ , —S(O) 2 NR 9 R 9′ , —NR 9 C(O)NR 9′ R 9″ , —SR 9 , —S(O)R 9 , —S(O) 2 R 9 , —CN, haloalkyl, haloalkoxy, —C(O)OR 9 and —C(O)NR 9 R 9′ ;

R 6 , R 6′ R 7 , and R 7′ are independently selected from the group consisting of hydrogen, halogen, —OR 9 , substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl unsubstituted heterocyclyl, unsubstituted aryl and unsubstituted cycloalkyl;

R 8 and R 8 ′ are independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl, with cycloalkyl, aryl, or heterocyclyl if substituted, being substituted by substituents selected from the group consisting of halogen, —R 9 , —OR 9 , —NO 2 , —NR 9 R 9′″ , NR 9 C(O)R 9′ , —NR 9 S(O) 2 R 9′ , —S(O) 2 NR 9 R 9′ , —NR 9 C(O)NR 9′ R 9″ , —SR 9 , —S(O)R 9 , —S(O) 2 R, —CN, -haloalkyl, and haloalkoxy;

R 9 , R 9′ and R 9″ , are independently selected from the group consisting of hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, and unsubstituted C 2 a alkynyl;

R 9′″ is selected from the group consisting of hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl and -Boc;

R 10 and R 10′ are independently selected from the group consisting of hydrogen, halogen, —OR 9 , substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted —O— C 1-6 alkyl, substituted or unsubstituted —O— C 2-6 alkenyl and substituted or unsubstituted —O— C 2-6 alkynyl;

wherein the alkyl, alkenyl or alkynyl moieties as defined for R 2 , R 3 , R 3′ , R 4 , R 4′ , R 5 , R 6 , R 6′ , R 7 , R 7′ , R 8 , R 8′ , R 10 and R 10′ are unsubstituted or substituted by one or more substituents selected from the group consisting of halogen, —OR 9 , —SR 9 , —CN, -haloalkyl, -haloalkoxy and —NR 9 R 9′″ ;

optionally as a stereoisomer, including enantiomers and diastereomers, a racemate or in form of a mixture of at least two stereoisomers, including enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof,

with the following provisos applying:

when Y is

with R 3 and R 3′ being hydrogen, R 1 being C(O)R 5 , and

—(CH 2 ) n —X—R 2 is alkyl, then said alkyl contains 6 or less C-atoms; and

when Y is

with R 3 and R 3′ being hydrogen, R 1 being C(O)R 5 , and X not being —C(R 4 R 4′ )—, then n is 2;

the following compounds are excluded from formula (I):

2. The compound according to claim 1 , wherein

R 3 and R 3 ′ are independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl and substituted or unsubstituted cycloalkyl, with cycloalkyl, if substituted, being substituted by substituents selected from halogen, —R 9 , and —OR 9 ;

and

R 4 is hydrogen, —OR 8 , substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, —C(O)OR 9 , —C(O)NR 9 R 9 ′, —NR 9 C(O)R 9′ , or —NR 9 R 9′″ ;

optionally as a stereoisomer, including enantiomers and diastereomers, a racemate or in form of a mixture of at least two stereoisomers, including enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

3. The compound according to claim 1 , wherein

R 2 is substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heterocyclyl; with cycloalkyl, aryl, or heterocyclyl, if substituted, being substituted by substituents selected from the group consisting of halogen, —R 9 , —OR 9 , —NO 2 , —NR 9 R 9′″ , NR 9 C(O)R 9′ , —NR 9 SO2R 9′ , —S(O) 2 NR 9 R 9′ , —NR 9 C(O)NR 9′ R 9″ , —SR 9 , —S(O)R 9 , S(O) 2 R 9 , —CN, haloalkyl, haloalkoxy, —C(O)OR 9 , —C(O)NR 9 R 9′ , ═O, —OCH 2 CH 2 OH, —NR 9 S(O) 2 NR 9″ R 9″ ;

R 9 , R 9′ , and R 9″ are independently selected from the group consisting of hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, and unsubstituted C 2-6 alkynyl;

R 9′″ is selected from the group consisting of hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl and -Boc;

wherein

the aryl is phenyl, naphthyl, or anthracene;

the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur,

and the cycloalkyl is C 3-8 cycloalkyl;

optionally as a stereoisomer, including enantiomers and diastereomers, a racemate or in form of a mixture of at least two stereoisomers, including enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

4. The compound according to claim 3 , wherein the C 1-6 alkyl is isopropyl; the C 2-6 alkenyl is ethenyl, propenyl, butenyl, pentenyl, or hexenyl; the C 2-6 alkynyl is ethynyl, propynyl, butynyl, pentynyl, or hexynyl; the cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl; the aryl is phenyl; and the heterocyclyl is pyridine, piperidine, thiazole, or morpholine.

5. The compound according to claim 1 , wherein

R 3 and R 3 ′ are independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted alkylheterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, with cycloalkyl, heterocyclyl or aryl, if substituted, also in alkylaryl, alkylcycloalkyl or alkylheterocyclyl, being substituted by substituents selected from the group consisting of halogen, —R 9 , and —OR 9 ;

R 9 , and R 9′ are independently selected from the group consisting of hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, and unsubstituted C 2-6 alkynyl;

wherein

the aryl is phenyl, naphthyl, or anthracene;

the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;

the alkyl is C 1-6 alkyl;

and

the cycloalkyl is C 3-8 cycloalkyl;

optionally as a stereoisomer, including enantiomers and diastereomers, a racemate or in form of a mixture of at least two stereoisomers, including enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

6. The compound according to claim 5 , wherein the C 1-6 alkyl is methyl or isopropyl; the C 2-6 alkenyl is ethenyl, propenyl, butenyl, pentenyl, or hexenyl; the C 2-6 is ethynyl, propynyl, butynyl, pentynyl, or hexynyl; the cycloalkyl is cyclopropyl; the aryl is phenyl; and the heterocyclyl is imidazole, oxadiazole, tetrazole, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, benzothiazole, tetrahydropyrane, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotriazole, benzodioxolane, benzodioxane, carbazole or quinazoline.

7. The compound according to claim 5 , wherein R 3 and R 3′ are independently selected from the group consisting of hydrogen and unsubstituted C 1-6 alkyl.

8. The compound according to claim 1 , wherein

X is a bond, —C(O)O—, —C(O)NR 8 —, —C(O)—, —O— or —C(R 4 R 4′ )—, wherein

R 4 is hydrogen, —OR 8 , substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, —COOR 9 , —CONR 9 R 9 ′, —NR 9 COR 9′ , or —NR 9 R 9′″ ;

R 4′ is hydrogen, or substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl or substituted or unsubstituted C 2-6 alkynyl;

R 8 and R 8 ′ are independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl,

R 9 , R 9′ and R 9″ are independently selected from the group consisting of hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, and unsubstituted C 2-6 alkynyl;

R 9′″ is selected from the group consisting of hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl and -Boc;

wherein

the aryl is phenyl, naphthyl, or anthracene;

and

the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;

optionally as a stereoisomer, including enantiomers and diastereomers, a racemate or in form of a mixture of at least two stereoisomers, including enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

9. The compound according to claim 8 , wherein the C 1-6 alkyl is methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; the C 2-6 alkenyl is ethenyl, propenyl, butenyl, pentenyl, or hexenyl; the C 2-6 alkynyl is ethynyl, propynyl, butynyl, pentynyl, or hexynyl; the aryl is phenyl; and the heterocyclyl is imidazole, oxadiazole, tetrazole, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, benzothiazole, tetrahydropyrane, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotriazole, benzodioxolane, benzodioxane, carbazole or quinazoline.

10. The compound according to claim 1 , wherein

R 5 is substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkyl aryl, substituted or unsubstituted alkyl heterocyclyl, substituted or unsubstituted alkyl cycloalkyl, or —NR 8 R 8′ , wherein the cycloalkyl, aryl or heterocyclyl groups, if substituted, also in alkyl aryl, alkyl heterocyclyl, alkyl cycloalkyl, are substituted by substituents selected from the group consisting of halogen, —R 9 , —OR 9 , —NO 2 , —NR 9 R 9′″ , —NR 9 C(O)R 9′ , —NR 9 S(O) 2 R 9′ , —S(O) 2 NR 9 R 9′ , —NR 9 C(O)NR 9′ R 9″ , —SR 9 , —S(O)R 9 , —S(O) 2 R 9 , —CN, haloalkyl, haloalkoxy, —C(O)OR 9 and —C(O)NR 9 R 9′ ;

R 8 and R 8 ′ are independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl;

R 9 , R 9′ and R 9″ are independently selected from the group consisting of hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, and unsubstituted C 2-6 alkynyl;

R 9′″ is selected from the group consisting of hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl and -Boc;

wherein

the aryl is phenyl, naphthyl, or anthracene;

the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms from the group consisting of nitrogen, oxygen and sulfur;

the alkyl is C 1-6 alkyl;

and

the cycloalkyl is C 3-8 cycloalkyl;

optionally as a stereoisomer, including enantiomers and diastereomers, a racemate or in form of a mixture of at least two stereoisomers, including enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

11. The compound according to claim 10 , wherein the C 1-6 alkyl is methyl, ethyl, or isopropyl; the C 2-6 alkenyl is ethenyl, propenyl, butenyl, pentenyl, or hexenyl; the C 2-6 alkynyl is ethynyl, propynyl, butynyl, pentynyl, or hexynyl; the cycloalkyl is cyclopropyl; the aryl is phenyl; and the heterocyclyl is pyridine, thiazole, tetrahydropyran or piperidine.

12. The compound according to claim 1 , wherein

R 6 , R 6′ R 7 , and R 7′ are independently selected from the group consisting of hydrogen, halogen, —OR 9 , substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, unsubstituted heterocyclyl, unsubstituted aryl and unsubstituted cycloalkyl;

R 9 , R 9′ and R 9″ are independently selected from the group consisting of hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl;

R 9′″ is selected from hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl and -Boc;

wherein

the aryl is phenyl, naphthyl, or anthracene;

the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;

and

the cycloalkyl is C 3-8 cycloalkyl;

optionally as a stereoisomer, including enantiomers and diastereomers, a racemate or in form of a mixture of at least two stereoisomers, including enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

13. The compound of claim 12 , wherein

the C 1-6 alkyl is methyl; the C 2-6 alkenyl is ethenyl, propenyl, butenyl, pentenyl, or hexenyl; the C 2-6 alkynyl is ethynyl, propynyl, butynyl, pentynyl, or hexynyl; the cycloalkyl is cyclopropyl; the aryl is phenyl; and the heterocyclyl is imidazole, oxadiazole, tetrazole, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, benzothiazole, tetrahydropyran, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, indole, benzotriazole, benzodioxolane, benzodioxane, carbazole or quinazoline.

14. The compound of claim 12 , wherein R 6 , R 6′ R 7 , and R 7′ are hydrogen.

15. The compound according to claim 1 , wherein

R 10 and R 10′ are independently selected from the group consisting of hydrogen, halogen, —OR 9 , substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted —O— C 1-6 alkyl, substituted or unsubstituted —O—C 2-6 alkenyl or substituted or unsubstituted —O—C 2-6 alkynyl.

16. The compound according to claim 15 , wherein the C 1-6 alkyl is methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; the C 2-6 alkenyl is ethenyl, propenyl, butenyl, pentenyl, or hexenyl; and the C 2-6 alkynyl is ethynyl, propynyl, butynyl, pentynyl, or hexynyl.

17. The compound according to claim 15 , wherein R 10 and R 10′ are hydrogen.

18. The compound according to claim 1 , wherein the compound of formula I is a compound of formula I′

wherein

Y is

q is 1, 2, 3, 4, 5 or 6;

R 1 is C(O)R 5 or S(O 2 )R 5 ;

R 2 is substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heterocyclyl, with cycloalkyl, aryl, or heterocyclyl, if substituted, being substituted by substituents selected from the group consisting of halogen, —R 9 , —OR 9 , —NO 2 , —NR 9 R 9′″ , —NR 9 C(O)R 9′ , —NR 9 S(O) 2 R 9′ , —S(O) 2 NR 9 R 9′ , —NR 9 C(O)NR 9′ R 9″ , —SR 9 , —S(O)R 9 , S(O) 2 R 9 , —CN, haloalkyl, haloalkoxy, —C(O)OR 9 , —C(O)NR 9 R 9′ , ═O, —OCH 2 CH 2 OH, —NR 9 S(O) 2 NR 9′ R 9″ ;

R 3 and R 3 ′ are independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, and substituted or unsubstituted cycloalkyl, with cycloalkyl, if substituted, being substituted by substituents selected from the group consisting of halogen, —R 9 , and —OR 9 ;

R 5 is substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkyl aryl, substituted or unsubstituted alkyl heterocyclyl, substituted or unsubstituted alkyl cycloalkyl, or —NR 8 R 8′ , wherein the cycloalkyl, aryl or heterocyclyl, if substituted, also in alkylaryl, alkylcycloalkyl or alkylheterocyclyl, being substituted by substituents selected from the group consisting of halogen, —R 9 , —OR 9 , —NO 2 , NR 9 R 9′″ , —NR 9 C(O)R 9′ , —NR 9 S(O) 2 R 9′ , —S(O) 2 NR 9 R 9′ , —NR 9 C(O)NR 9′ R 9″ , —SR 9 , —S(O)R 9 , —S(O) 2 R 9 , —CN, haloalkyl, haloalkoxy, —C(O)OR 9 and —C(O)NR 9 R 9′ ;

R 6 , R 6′ R 7 , and R 7′ are independently selected from the group consisting of hydrogen, halogen, —OR 9 , substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, unsubstituted heterocyclyl, unsubstituted aryl and unsubstituted cycloalkyl;

R 8 and R 8 ′ are independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl, with cycloalkyl, aryl, or heterocyclyl if substituted, being substituted by substituents selected from the group consisting of halogen, —R 9 , —OR 9 , —NO 2 , —NR 9 R 9′″ , NR 9 C(O)R 9′ , —NR 9 S(O) 2 R 9′ , —S(O) 2 NR 9 R 9′ , —NR 9 C(O)NR 9′ R 9″ , —SR 9 , —S(O)R 9 , —S(O) 2 R 9 , —CN, -haloalkyl, and haloalkoxy;

R 9 , R 9′ and R 9″ are independently selected from the group consisting of hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl;

R 9′″ is selected from the group consisting of hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl and -Boc;

R 10 and R 10′ are independently selected from the group consisting of hydrogen, halogen, —OR 9 , substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted —O— C 1-6 alkyl, substituted or unsubstituted —O—C 2-6 alkenyl, and substituted or unsubstituted —O—C 2-6 alkynyl;

wherein the alkyl, alkenyl or alkynyl moieties as defined for R 2 , R 3 , R 3′ , R 5 , R 6 , R 6′ , R 7 , R 7′ , R 8 , R 8′ , R 10 and R 10′ are unsubstituted or substituted by one or more substituents selected from the group consisting of halogen, —OR 9 , —SR 9 , —CN, -haloalkyl, -haloalkoxy and —NR 9 R 9′″ ;

optionally as a stereoisomer, including enantiomers and diastereomers, a racemate or in form of a mixture of at least two stereoisomers, including enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof,

with the following proviso applying:

when Y is

and

(CH 2 ) 2 —R 2 is alkyl, then said alkyl contains 6 or less C-atoms.

19. The compound according to claim 1 , wherein the compound of formula I is a compound of formula I″

wherein

R 1 is C(O)R 5 or S(O 2 )R 5 ;

R 2 is substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heterocyclyl, with cycloalkyl, aryl, or heterocyclyl, if substituted, being substituted by substituents selected from the group consisting of halogen, —R 9 , —OR 9 , —NO 2 , —NR 9 R 9′″ , NR 9 C(O)R 9′ , —NR 9 S(O) 2 R 9′ , —S(O) 2 NR 9 R 9′ , —NR 9 C(O)NR 9′ R 9″ , —SR 9 , —S(O)R 9 , S(O) 2 R 9 , —CN, haloalkyl, haloalkoxy, —C(O)OR 9 , —C(O)NR 9 R 9′ , ═O, —OCH 2 CH 2 OH, —NR 9 S(O) 2 NR 9′ R 9″ ;

R 3 and R 3 ′ are independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl and substituted or unsubstituted cycloalkyl, with cycloalkyl, if substituted, being substituted by substituents selected from the group consisting of halogen, —R 9 , and —OR 9 ;

R 5 is substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkyl aryl, substituted or unsubstituted alkyl heterocyclyl and substituted or unsubstituted alkyl cycloalkyl, or —NR 8 R 8 , wherein the cycloalkyl, aryl or heterocyclyl, if substituted, also in alkylaryl, alkylcycloalkyl or alkylheterocyclyl, being substituted by substituents selected from the group consisting of halogen, —R 9 , —OR 9 , —NO 2 , —NR 9 R 9′″ , —NR 9 C(O)R 9′ , —NR 9 S(O) 2 R 9′ , —S(O) 2 NR 9 R 9′ , —NR 9 C(O)NR 9′ R 9″ , —SR 9 , —S(O)R 9 , —S(O) 2 R 9 , —CN, haloalkyl, haloalkoxy, —C(O)OR 9 and —C(O)NR 9 R 9″ ;

R 8 and R 8 ′ are independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl, with cycloalkyl, aryl, or heterocyclyl if substituted, being substituted by substituents selected from the group consisting of halogen, —R 9 , —OR 9 , —NO 2 , —NR 9 R 9′″ , NR 9 C(O)R 9′ , —NR 9 S(O) 2 R 9′ , —S(O) 2 NR 9 R 9′ , —NR 9 C(O)NR 9′ R 9″ , —SR 9 , —S(O)R 9 , —S(O) 2 R 9 , —CN, -haloalkyl, and haloalkoxy;

R 9 , R 9′ and R 9″ are independently selected from the group consisting of hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, and unsubstituted C 2-6 alkynyl;

R 9′″ is selected from the group consisting of hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl and -Boc;

R 10 and R 10′ are independently selected from the group consisting of hydrogen, halogen, —OR 9 , substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted —O—C 1-6 alkyl, substituted or unsubstituted —O— C 2-6 alkenyl, and substituted or unsubstituted —O—C 2-6 alkynyl;

wherein the alkyl, alkenyl or alkynyl moieties as defined for R 2 , R 3 , R 3′ , R 5 , R 8 , R 8′ , R 10 and R 10′ are unsubstituted or substituted by one or more substituents selected from the group consisting of halogen, —OR 9 , —SR 9 , —CN, -haloalkyl, -haloalkoxy and —NR 9 R 9′″ ;

optionally as a stereoisomer, including enantiomers and diastereomers, a racemate or in form of a mixture of at least two stereoisomers, including enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof,

with the following proviso applying:

when —(CH 2 ) 2 —R 2 is alkyl, then said alkyl contains 6 or less C-Atoms.

20. The compound according to claim 5 , wherein the compound of formula I is a compound of formula I′″

wherein

R 1 is C(O)R 5 or S(O 2 )R 5 ;

R 2 is substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heterocyclyl, with cycloalkyl, aryl, or heterocyclyl, if substituted, being substituted by substituents selected from the croup consisting of halogen, —R 9 , —OR 9 , —NO 2 , —NR 9 R 9′″ , NR 9 C(O)R 9′ , —NR 9 S(O) 2 R 9′ , —S(O) 2 NR 9 R 9′ , —NR 9 C(O)NR 9′ R 9″ , —SR 9 , —S(O)R 9 , S(O) 2 R 9 , —CN, haloalkyl, haloalkoxy, —C(O)OR 9 , —C(O)NR 9 R 9′ , ═O, —OCH 2 CH 2 OH, —NR 9 S(O) 2 NR 9′ R 9″ ;

R 5 is substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkyl aryl, substituted or unsubstituted alkyl heterocyclyl and substituted or unsubstituted alkyl cycloalkyl, or —NR 8 R 8′ , wherein the cycloalkyl, aryl or heterocyclyl, if substituted, also in alkylaryl, alkylcycloalkyl or alkylheterocyclyl, being substituted by substituents selected from the group consisting of halogen, —R 9 , —OR 9 , —NO 2 , —NR 9 R 9′″ , —NR 9 C(O)R 9′ , —NR 9 S(O) 2 R 9′ , —S(O) 2 NR 9 R 9′ , —NR 9 C(O)NR 9′ R 9″ , —SR 9 , —S(O)R 9 , —S(O) 2 R 9 , —CN, haloalkyl, haloalkoxy, —C(O)OR 9 and —C(O)NR 9 R 9′ ;

R 7 and R 7′ are independently selected from the group consisting of hydrogen, halogen, —OR 9 , substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, unsubstituted heterocyclyl, unsubstituted aryl, and unsubstituted cycloalkyl;

R 8 and R 8 ′ are independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heterocyclyl, with cycloalkyl, aryl, or heterocyclyl if substituted, being substituted by substituents selected from the group consisting of halogen, —R 9 , —OR 9 , —NO 2 , —NR 9 R 9′″ , NR 9 C(O)R 9′ , —NR 9 S(O) 2 R 9′ , —S(O) 2 NR 9 R 9′ , —NR 9 C(O)NR 9′ R 9″ , —SR 9 , —S(O)R 9 , —S(O) 2 R 9 , —CN, -haloalkyl, and haloalkoxy;

R 9 , R 9′ and R 9″ are independently selected from the group consisting of hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, and unsubstituted C 2-6 alkynyl;

R 9′″ is selected from the group consisting of hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl and -Boc;

R 10 and R 10′ are independently selected from the group consisting of hydrogen, halogen, —OR 9 , substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted —O—C 1-6 alkyl, substituted or unsubstituted —O—C 2-6 alkenyl or substituted or unsubstituted —O—C 2-6 alkynyl;

wherein the alkyl, alkenyl or alkynyl moieties as defined for R 2 , R 5 , R 7 , R 7′ , R 8 , R 8′ , R 10 and R 10′ are unsubstituted or substituted by one or more substituents selected from the group consisting of halogen, —OR 9 , —SR 9 , —CN, -haloalkyl, -haloalkoxy and —NR 9 R 9′″ ;

optionally as a stereoisomer, including enantiomers and diastereomers, a racemate or in form of a mixture of at least two stereoisomers, including enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.

21. The compound according to claim 1 , which is selected from the group consisting of:

(2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

(2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(pyridin-2-yl)methanone

1-(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)-2-phenylethanone

(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(pyridin-3-yl)methanone

(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(pyridin-4-yl)methanone

(4-chloropyridin-2-yl)(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

(2-methoxyphenyl)(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

(2-fluorophenyl)(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

1-(2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)ethanone

cyclopropyl(2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(thiazol-4-yl)methanone

(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(thiazol-2-yl)methanone

(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(thiazol-5-yl)methanone

1-(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)-2-(pyridin-3-yl)ethanone

1-(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)-2-(tetrahydro-2H-pyran-4-yl)ethanone

(3-methoxyphenyl)(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(tetrahydro-2H-pyran-4-yl)methanone

1-(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)-2-(pyridin-2-yl)ethanone

2-cyclopropyl-1-(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)ethanone

(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(5-(trifluoromethyl)pyridin-2-yl)methanone

(5-fluoropyridin-2-yl)(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanol

(5-chloropyridin-2-yl)(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(6-(trifluoromethyl)pyridin-3-yl)methanone

(3-fluoropyridin-2-yl)(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

(5-fluoropyridin-3-yl)(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

(2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(5-(trifluoromethyl)pyridin-2-yl)methanone

(5-fluoropyridin-2-yl)(2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

(5-chloropyridin-2-yl)(2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

8-phenethyl-12-[(pyridin-2-yl)carbonyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane

12-[(5-chloropyridin-2-yl)carbonyl]-8-phenethyl-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane

(3-fluoropyridin-2-yl)(2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

(5-fluoropyrid in-3-yl)(2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

(2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone

(5-chloropyridin-3-yl)(2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

(2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(5-(trifluoromethyl)pyridin-3-yl)methanone

(9-(2-(3-chloropyridin-2-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

(2-methyl-9-(2-(6-(trifluoromethyl)pyridin-2-yl)ethyl)-1-oxa-4,9-diazaspiro[s 0.5]undecan-4-yl)(phenyl)methanone

(9-(2-(5-chloropyridin-2-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

6-(2-(4-benzoyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)nicotinonitrile

(2-methyl-9-(2-(3-(trifluoromethyl)pyridin-2-yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

(2-methyl-9-(2-(5-(trifluoromethyl)pyridin-2-yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

(2-methyl-9-(2-(4-(trifluoromethyl)pyridin-2-yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

(2-methyl-9-(2-(3-nitropyridin-2-yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

(9-(2-(6-aminopyridin-2-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

(2-methyl-9-(2-(2-nitropyridin-3-yl)ethyl)-1-oxa-49-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

(9-(2-(3-chloropyridin-2-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(2,6-difluorophenyl)methanone

(9-(2-(3-chloropyridin-2-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(pyridin-2-yl)methanone

(9-(2-(3-chloropyridin-2-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-Yl)(2-fluorophenyl)methanone

(9-(2-(3-chloropyridin-4-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

(9-(2-(3-fluoropyridin-4-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

(9-(2-(5-fluoropyridin-2-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

(9-(2-(3-fluoropyridin-2-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

8-(2-(3-fluoropyridin-2-yl)ethyl)-12-[(2-fluorophenyl)carbonyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane

1-(9-(2-(3-fluoropyridin-2-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)propan-1-one

8-(2-(3-fluoropyridin-2-yl)ethyl)-12-[(cyclopropyl)carbonyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane

8-(2-(3-fluoropyridin-2-yl)ethyl)-12-[(2,6-difluorophenyl)carbonyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane

8-(2-(3-chloropyridin-2-yl)ethyl)-12-[(2,6-difluorophenyl)carbonyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane

(2-fluorophenyl)(9-(2-(3-fluoropyridin-2-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

(2,6-difluorophenyl)(9-(2-(3-fluoropyridin-2-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

(9-(2-hydroxy-2-phenylethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

(9-(2-methoxyphenethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone phenyl(9-(2-(pyridin-2-yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

9-phenethyl-N-phenyl-1-oxa-4,9-diazaspiro[5.5]undecane-4-carboxamide

cyclopropyl(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(pyridin-2-yl)methanone

N-methyl-9-phenethyl-N-phenyl-1-oxa-4,9-diazaspiro[5.5]undecane-4-carboxamide

(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(piperidin-1-yl)methanone

phenyl(9-(3-(trifluoromethoxy)phenethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

phenyl(9-(2-(6-(trifluoromethyl)pyridin-3-yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

phenyl(9-(2-(pyridin-3-yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

(2-methyl-9-(2-(pyridin-3-yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

(9-(2-(6-methoxypyridin-2-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecane-4-yl)(phenyl)methanone

(2-methyl-9-(2-(pyridin-4-yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecane-4-yl)(phenyl)methanone

4-(2-(4-benzoyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)benzenesulfonamide

(2-methyl-9-(2-(6-(trifluoromethyl)pyridin-3-yl)ethyl)-1-oxa-4-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

4-(2-(4-benzoyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)-N-methylbenzenesulfonamide

tert-butyl (4-(2-(4-(5-chloropicolinoyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)thiazol-2-yl)carbamate

tert-butyl (4-(2-(4-benzoyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)thiazol-2-yl)carbamate

(2-methyl-9-(3-(trifluoromethoxy)phenethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(pyridin-2-yl)methanone

(2-methyl-9-(2-nitrophenethyl)-1-oxa-49-diazaspiro[5.5]undecan-4-yl)(Phenyl)methanone

(2-methyl-9-(3-nitrophenethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(Phenyl)methanone

9-phenethyl-4-(phenylsulfonyl)-1-oxa-4,9-diazaspiro[5.5]undecane

4-(isopropylsulfonyl)-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecane

(2-methyl-9-(3-phenylpropyl)-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

(9-isopentyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

(2-methyl-9-(2-(pyridin-2-yl)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

(9-(2-isopropoxyethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

2-(4-benzoyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)-1-morpholinoethanone

2-(4-benzoyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)-1-(piperidin-1-yl)ethanone

1-(9-(2-fluorophenethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)propan-1-one

(9-(2-(5-chloropyridin-3-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

(9-(2-(5-fluoropyrid in-3-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

8-(2-fluorophenethyl)-12-[(pyridin-2-yl)carbonyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane

1-(2-isopropyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)ethanone cyclopropyl(2-isopropyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

(9-(3-nitrophenethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

(9-benzyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

(9-(2-hydroxyphenethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

(3-hydroxyphenyl) (9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

(2-hydroxyphenyl)(9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

(9-(2-(2-aminothiazol-4-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(5-chloropyridin-2-yl)methanone

(9-(2-(2-aminothiazol-4-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

(9-(3-aminophenethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

(9-(2-aminophenethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

(9-(3-aminophenethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

(9-(2-(3-aminopyridin-2-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

(9-(2-(2-aminopyridin-3-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(phenyl)methanone

1-(3-(2-(4-benzoyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenyl)urea

1-(2-(2-(4-benzoyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenyl)urea

N-(3-(2-(4-benzoyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenyl)acetamide

N-(2-(2-(4-benzoyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenyl)acetamide

N-(3-(2-(4-benzoyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenyl)acetamide

N-(3-(2-(4-benzoyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenyl)methanesulfonamide

2-methyl-9-phenethyl-4-(phenylsulfonyl)-1-oxa-4,9-diazaspiro[5.5]undecane

4-(isopropylsulfonyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan

N,N-dimethyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecane-4-carboxamide

N,N,2-trimethyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecane-4-carboxamide

N-methyl-9-phenethyl-N-(pyridin-2-yl)-1-oxa-4,9-diazaspiro[5.5]undecane-4-carboxamide

N-cyclopropyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecane-4-carboxamide

9-phenethyl-N-(pyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecane-4-carboxamide

N-cyclopropyl-N-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecane-4-carboxamide

N-methyl-9-phenethyl-N-(pyridin-3-yl)-1-oxa-4,9-diazaspiro[5.5]undecane-4-carboxamide

(R)-(2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(pyridin-2-yl)methanone

(S)-(2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)(pyridin-2-yl)methanone

8-(2-(3-fluoropyridin-2-yl)ethyl)-12-[(2,3-difluorophenyl)carbonyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane

8-(2-(3-fluoropyridin-2-yl)ethyl)-12-[(2,4-difluorophenyl)carbonyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane

2-(2-(12-(2-fluorobenzoyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl)ethyl)nicotinonitrile

8-(2-(3-fluoropyridin-2-yl)ethyl)-12-[(2,5-difluorophenyl)carbonyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane

12-[(2-fluorophenyl)carbonyl]-8-(2-(3-methoxypyrid in-2-yl)ethyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane

(2-fluorophenyl)(9-(2-(3-fluoropyridin-2-yl)ethyl)-2,2-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

12-[(3-fluorophenyl)carbonyl]-8-(2-(3-fluoropyridin-2-yl)ethyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane

12-[(4-fluorophenyl)carbonyl]-8-(2-(3-fluoropyridin-2-yl)ethyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane

8-(2-(3-fluoropyridin-2-yl)ethyl)-12-[(2-methoxyphenyl)carbonyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane

2-(8-(2-(3-fluoropyridin-2-yl)ethyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane-12-carbonyl)benzonitrile

12-[(2-chlorophenyl)carbonyl]-8-(2-(3-fluoropyridin-2-yl)ethyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane

(2,3-difluorophenyl)(9-(2-(3-fluoropyridin-2-yl)ethyl)-2,2-dimethyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

8-(2-(3-chloropyridin-2-yl)ethyl)-12-[(2,3-difluorophenyl)carbonyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane

12-[(2-fluorophenyl)carbonyl]-8-(2-(6-methoxypyridin-2-yl)ethyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane

methyl 3-(12-(2,6-difluorobenzoyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-8-yl)propanoate

12-[(2,6-difluorophenyl)carbonyl]-8-(2-(6-methoxypyridin-2-yl)ethyl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane

8-(2,5-difluorophenethyl)-12-[(2,6-difluorophenyl)carbonyl]-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane

(R)-(2-fluorophenyl)(9-(2-(3-fluoropyridin-2-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

(S)-(2-fluorophenyl)(9-(2-(3-fluoropyrid in-2-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

(R)-(2,6-difluorophenyl)(9-(2-(3-fluoropyridin-2-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

(S)-(2,6-difluorophenyl)(9-(2-(3-fluoropyrid in-2-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

(2,3-difluorophenyl)(9-(2-(3-fluoropyridin-2-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

(2,4-difluorophenyl)(9-(2-(3-fluoropyridin-2-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

(2,5-difluorophenyl)(9-(2-(3-fluoropyridin-2-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

(2-chlorophenyl)(9-(2-(3-fluoropyrid in-2-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone

(3-fluorophenyl)(9-(2-(3-fluoropyridin-2-yl)ethyl)-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-4-yl)methanone,

optionally as a stereoisomer, including enantiomers and diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, including enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.

22. A process for the production of a compound of formula I according to claim 1 ,

wherein a compound of formula VH or its suitable salt,

is reacted with a compound according to formula VI, VII or VIII

wherein LG is a leaving group.

23. A process for the preparation of a compound of formula I″ according to claim 19

comprising

(a) reacting a compound of formula XIIx

with a compound of formula XIIIx

wherein LG and G are leaving groups to obtain a compound of formula XIVx

wherein LG is a leaving group,

(b) carrying out a cyclization of the resulting compound of formula XIVx in a suitable A solvent; in the presence of a strong base; and at a suitable temperature, comprised between −78° C. and the reflux temperature, such as cooling, to obtain a compound of formula XVx

(c) and carrying out a reduction reaction by using a suitable reducing agent in a suitable solvent, at a suitable temperature comprised between room temperature and the reflux temperature, to yield a compound of formula I″.

24. A process for the preparation of a compound of formula I′″ according to claim 20

wherein R 1 , R 10 and R 10′ are as defined in claim 20 and R 7 and R 7′ are both hydrogen, comprising

(a) dehydration of a compound of formula XXIx

wherein R 6 and R 6′ are both hydrogen,

with a dehydrating agent, in a suitable solvent, at a suitable temperature, and

(b) cyclopropanation of the resulting compound of formula XVax

wherein R 6 and R 6′ are both hydrogen,

using a suitable methyl-transfer reagent, in a suitable aprotic solvent, and in the presence of a strong base, at a suitable temperature.

25. A pharmaceutical composition which comprises the compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

26. A method of treating pain in a subject in need thereof, comprising administration of an effective amount of the compound according to claim 1 .

27. The method according to claim 26 , wherein the pain is selected from the group consisting of medium to severe pain, visceral pain, chronic pain, cancer pain, migraine, inflammatory pain, acute pain or neuropathic pain, allodynia and hyperalgesia.

Assignments (2)
CHANGE OF NAME Recorded May 1, 2019
From: LABORATORIOS DEL DR. ESTEVE S.A.
To: ESTEVE PHARMACEUTICALS, S.A.
Reel/Frame 049837/0469 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2017
From: VIRGILI-BERNADO, MARINA; ALONSO-XALMA, MONICA; ALEGRET-MOLINA, CARLOS; ALMANSA-ROSALES, CARMEN; MERCE-VIDAL, RAMÓN
To: LABORATORIOS DEL DR. ESTEVE S.A.
Reel/Frame 041859/0921 →
Priority Claims (1)
EP 14382208 · Jun 2, 2014 · regional
Continuity (1)
Related Publication 20170197984A1 · Jul 13, 2017